Paclitaxel 200mg/m2

DRUG2 trials

Conditions

Gastric CancerHead and Neck CancerMelanomaNon Small Cell Lung CancerNon-Small Cell Lung CancerRenal Cell CarcinomaResectable Non-Small-Cell Lung CancerSolid Tumor

Phase 1

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

RecruitingNCT04198766

Inhibrx Biosciences, IncSolid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer +5

Start: 2019-12-10End: 2033-07-01Target: 340Updated: 2026-07-29

Phase 2

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients

CompletedNCT03081689

Spanish Lung Cancer GroupNon Small Cell Lung Cancer

Start: 2017-04-15End: 2023-10-18Updated: 2024-12-04

2026-06-17

Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non–small cell lung cancer.

Journal of Clinical Oncology2026-05-28

Decoding B Cell Signatures of Complete Pathological Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.

2026-03-10

INBRX-106, a novel Hexavalent OX40 agonist, potentiates T-cell receptor clustering, leading to improved activation and potent anti-tumor responses 3058

The Journal of Immunology2025-11-01

Abstract B020: NETosis-specific clipped histone H3 is a novel biomarker of response to neoadjuvant chemo-immunotherapy in resectable lung cancer

Cancer Immunology Research2025-09-24

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)

OncoImmunology2025-06-051 citations

HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.

Journal of Clinical Oncology2025-05-28

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering

Journal for ImmunoTherapy of Cancer2025-05-014 citations

Abstract 4542: B cells mediate antitumor immune response and predict pathological response in locally advanced NSCLC patients treated with perioperative chemoimmunotherapy (NADIM trials)

Cancer Research2025-04-21

Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.

2024-10-1437 citations

Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer

Journal for ImmunoTherapy of Cancer2024-10-0111 citations

748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

Regular and Young Investigator Award Abstracts2023-10-311 citations

1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice

Regular and Young Investigator Award Abstracts2023-10-31

Association of peripheral memory B cell population maintenance and long term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial).

Journal of Clinical Oncology2023-06-01

Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer

Frontiers in Oncology2023-05-1510 citations

Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non–small cell lung cancer.

Journal of Clinical Oncology2022-06-013 citations

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Journal of Clinical Oncology2022-05-16318 citations

856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors

Regular and Young Investigator Award Abstracts2021-11-019 citations

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

Clinical Cancer Research2021-08-1061 citations

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

Journal for ImmunoTherapy of Cancer2021-08-0112 citations

9 more papers not shown

Paclitaxel 200mg/m2

Sponsors

Conditions

Phase 1

Phase 2

Related Papers